Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Arthritis and children: What is JIA?
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children and adolescents under the age of 16. It is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the joints. This results in symptoms such as joint pain, swelling, stiffness, and reduced mobility. JIA can affect one or multiple joints and, in some cases, may also involve other organs, such as the eyes or skin.
There are several subtypes of JIA, each with different characteristics and levels of severity. While the exact cause is unknown, a combination of genetic and environmental factors is believed to play a role. Early diagnosis and treatment are crucial in managing JIA, as they can prevent long-term joint damage and improve the child’s quality of life. Treatment typically includes medications like NSAIDs, DMARDs, or biologics, along with physical therapy to maintain joint function and mobility.
Therefore, get an overall knowledge of arthritis and children: what is JIA?
See More Webinars @ Hidoc Webinars
1.
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
2.
New CAR T-Cell Therapy Approved for Leukemia
3.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
4.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
5.
Guideline on management of early-stage non-small cell lung cancer released
1.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
2.
Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma
3.
Understanding Protein C Deficiency: Symptoms, Causes, and Treatment
4.
The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025
5.
Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Should We Use DARA Up Front As First-Line Therapy in MM?
3.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation